stoxline Quote Chart Rank Option Currency Glossary
  
Dominari Holdings Inc. (DOMH)
2.455  -0.035 (-1.41%)    03-28 10:04
Open: 2.44
High: 2.455
Volume: 1,105
  
Pre. Close: 2.49
Low: 2.44
Market Cap: 13(M)
Technical analysis
2024-03-28 9:45:19 AM
Short term     
Mid term     
Targets 6-month :  2.92 1-year :  3.41
Resists First :  2.5 Second :  2.92
Pivot price 2.23
Supports First :  2.14 Second :  1.91
MAs MA(5) :  2.36 MA(20) :  2.19
MA(100) :  2.19 MA(250) :  2.55
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  90.7 D(3) :  80.8
RSI RSI(14): 60.7
52-week High :  3.75 Low :  1.75
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ DOMH ] has closed below upper band by 12.4%. Bollinger Bands are 19% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.5 - 2.51 2.51 - 2.52
Low: 2.35 - 2.36 2.36 - 2.37
Close: 2.48 - 2.5 2.5 - 2.52
Company Description

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

Headline News

Sat, 23 Mar 2024
DOMH Stock Quote Price and Forecast - Dominari Holdings Inc. - CNN

Fri, 22 Mar 2024
Oppenheimer (NYSE:OPY) & Dominari (NASDAQ:DOMH) Head to Head Review - Defense World

Fri, 15 Mar 2024
Dominari Securities names Eric Newman EVP By Investing.com - Investing.com

Fri, 15 Mar 2024
Dominari Securities Appoints 30 Year Financial Industry Expert to Manage Operations and Compliance - PR Newswire

Tue, 12 Mar 2024
Dominari Securities LLC Expands Investment Banking Practice with Appointment of Experienced Financial Executive - Victoria Advocate

Thu, 07 Mar 2024
Dominari Securities LLC Continues to Add Depth with Three New Hires - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 6 (M)
Shares Float 4 (M)
Held by Insiders 41 (%)
Held by Institutions 8.7 (%)
Shares Short 3 (K)
Shares Short P.Month 6 (K)
Stock Financials
EPS -4.41
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 11.03
Profit Margin 0 %
Operating Margin -322.4 %
Return on Assets (ttm) -16.2 %
Return on Equity (ttm) -33.2 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0.17
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -19 (M)
Levered Free Cash Flow -17 (M)
Stock Valuations
PE Ratio -0.56
PEG Ratio 0
Price to Book value 0.22
Price to Sales 14.04
Price to Cash Flow -0.75
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android